Latest RPC1063 Stories

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC). Leading to the initiation of the RPC01-202 study, called TOUCHSTONE, Receptos successfully filed an Investigational New Drug (IND)...

SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate receptor 1 (S1P1) modulator, RPC1063, has been administered to the first patient in a Phase 2/3 study. RPC01-201, a Phase 2/3 placebo-controlled (Phase 2) and active comparator-controlled (Phase 3) trial, is the first of two planned pivotal studies for RPC1063 in the indication of relapsing multiple sclerosis (RMS). The Phase 2 portion of RPC01-201 is a randomized,...